Taiwanese Pharma Co. Says €142M Award Can't Be Enforced
Taiwanese drug developer PharmaEssentia Corp. is fighting the enforcement of a €142 million ($161.1 million) arbitral award issued to Austrian pharmaceutical company AOP Orphan following an ill-fated deal to develop a...To view the full article, register now.
Already a subscriber? Click here to view full article